3112 Ped BPDNCT04777357
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
At risk: Enrollment reduced 11%.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 96 versions: 48 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria shortened, about 10 words
- Primary endpoints: details revised at 1 of 9 entries
- Enrollment reduced: 380 → 338 participants
- Trial sites expanded: 81 → 87 locations
- Minor Site details revised at 1 of 81 sitesv94
- Minor Site details revised at 1 of 81 sitesv93
- Minor Site details revised at 1 of 81 sitesv92
- Minor Site details revised at 1 of 81 sitesv91
Show 43 earlier versionsHide 43 earlier versions
- Minor Site details revised at 1 of 81 sitesv90
- Minor Site details revised at 1 of 81 sitesv89
- Minor Site details revised at 3 of 81 sitesv88
- Minor Study sites: 80 to 81v87
- Minor Study sites: 79 to 80v86
- Minor Study sites: 78 to 79v85
- Minor Site details revised at 1 of 78 sitesv84
- Minor Study sites: 77 to 78v83
- Minor Study sites: 76 to 77v82
- Minor Study sites: 75 to 76v81
- Minor Study sites: 74 to 75v80
- Minor Site details revised at 1 of 74 sitesv79
- Minor Study sites: 73 to 74v78
- Minor Study sites: 72 to 73v77
- Minor Study sites: 71 to 72v76
- Minor Site details revised at 2 of 71 sitesv75
- Minor Site details revised at 2 of 71 sitesv74
- Minor Study sites revised (71)v73
- Minor Study sites: 70 to 71v72
- Minor Site details revised at 1 of 70 sitesv71
- Minor Study sites: 69 to 70v70
- Minor Site details revised at 1 of 69 sitesv69
- Minor Study sites: 68 to 69v68
- Minor Site details revised at 1 of 68 sitesv67
- Minor Site details revised at 1 of 68 sitesv66
- Minor Site details revised at 1 of 68 sitesv65
- Minor Primary and study completion dates: Mar 10, 2027 to Mar 2027v64
- Minor Study sites: 67 to 68v63
- Minor Study sites: 66 to 67v62
- Minor Site details revised at 1 of 66 sitesv61
- Minor Study sites: 63 to 66v60
- Notable Primary and study completion dates: Jan 29, 2025 to Mar 10, 2027
- Primary endpoints: 5 to 9
- Eligibility criteria expanded, about 4 words
- Study sites: 58 to 63
- Minor Study sites: 57 to 58v58
- Minor Site details revised at 1 of 57 sitesv56
- Minor Study sites: 56 to 57v55
- Minor Study sites: 55 to 56v54
- Minor Study sites: 54 to 55v53
- Minor Study sites: 53 to 54v52
- Minor Study sites revised (53)v51
- Minor Study sites: 52 to 53v50
- Minor Study sites: 50 to 52v49
- Minor Site details revised at 1 of 50 sitesv48
- Notable Eligibility criteria expanded, about 31 words
- Study sites: 49 to 50
- Study title expanded, about 2 words
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants with Adverse Events
Timeframe: Baseline (Week 0) to Week 10
Abnormal Change from Baseline in Vital Signs
Timeframe: Baseline (Week 0) to Week 10
Number of Participants with Incidence of Abnormal Clinical Laboratory Test Results
Timeframe: Baseline (Week 0) to Week 6
Change in Electrocardiogram (ECG)
Timeframe: Baseline (Week 0) to Week 6
Change From Baseline in Simpson-Angus Scale (SAS)
Timeframe: Baseline (Week 0) to Week 6
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
Timeframe: Baseline (Week 0) to Week 10
Change From Baseline in Barnes Akathisia Rating Scale (BARS)
Timeframe: Baseline (Week 0) to Week 6
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)
Timeframe: Baseline (Week 0) to Week 6
Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score
Timeframe: Baseline (Week 0) to Week 6
Arms and interventions
PlaceboPlacebo comparator
Participants will receive Placebo over a 6 week treatment period.
CariprazineExperimental
Participants will receive flexible dose Cariprazine over a 6 week treatment period.
Drugs: Cariprazine, Placebo
Sites
87 sites in 3 countries
United States 75, Russia 10, Puerto Rico 2